NervGen Pharma (NGEN) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NervGen Pharma (NGEN) has outperformed Sionna Therapeutics (SION) over the past year, losing 45.4% versus a loss of 87.8%. Sionna Therapeutics is the larger company by market cap ($175.6 million vs $171.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGEN | SION |
|---|---|---|
| Share price | $1.59 | $3.89 |
| Market cap | $170.96M | $175.63M |
| 1-day change | -1.85% | -4.66% |
| YTD return | -71.61% | -90.54% |
| 1-year return | -45.40% | -87.82% |
| 5-year return | -26.05% | — |
| EPS (TTM) | $-0.57 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-75.27M |
| 52-week high | $6.30 | $54.97 |
| 52-week low | $1.55 | $3.78 |
| Distance from 52-week high | -74.76% | -92.92% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +528.93% | +439.85% |
| Average volume | 507.49K | 2.22M |
| Shares outstanding | 107.52M | 45.15M |
| Employees | 9 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGEN has outperformed SION by 42.4 percentage points over the past year.
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
NGEN vs SION FAQ
Which is bigger, NervGen Pharma or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $175.63M compared with $170.96M for NervGen Pharma (NGEN).
Which stock has performed better over the past year, NGEN or SION?
NGEN returned -45.40% over the past 12 months, compared with -87.82% for SION (price return, excluding dividends). Past performance does not predict future results.
Are NervGen Pharma and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.